Table 1. Clinical data.

Subject	Age (years)	Disease duration (years)	LEDD (mg)		UPDRS-III (score)
			Pre-DBS	Post-DBS	Pre-DBS		Post-DBS
					Meds-off	Meds-on	Meds-off stim-off	Meds-off stim-on	Meds-on stim-off	Meds-on stim-on
wue03	61	18	2725	600	40	9	45	17	23	14
wue09	55	19	1200	730	50	11	33	16	8	11
wue04	54	7	658	400	26	8	27	5	9	8
wue02	65	10	1100	800	40	23	39	19	17	16
wue10	56	10	1200	550	69	14	65	25	20	5
wue07	61	10	650	220	43	24	29	15	8	9
wue06	51	11	1133	180	46	11	48	12	11	6
wue11	53	11	1300	460	55	4	51	9	13	14

Patients were evaluated with the UPDRS-III within one month prior to the implants (pre-DBS) after overnight (>12 h) suspension of all dopaminergic drugs (meds-off) and upon receiving 1 to 1.5-times (range 200–300 mg) the levodopa-equivalent of the morning dose (meds-on). After surgery (post-DBS), patients were also assessed with the UPDRS-III in four conditions: (i) stimulation off for at least two hours (stim-off); (ii) bilateral STN stimulation (stim-on); (iii) meds-on (as pre-DBS); (iv) meds-on and stim-on. Wue11 is the only female patient. DBS, deep brain stimulation; LEDD, levodopa equivalent daily dose; STN, subthalamic nucleus; UPDRS-III, Unified Parkinson Disease Rating.